INDIANAPOLIS, Oct. 6, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase results from the ixekizumab clinical development program during the 24th European Academy of Dermatology and Venereology Congress in Copenhagen, Denmark, Oct. 7-11. Ixekizumab is the company's investigational medicine for the treatment of moderate-to-severe plaque psoriasis.
A total of 13 presentations, including a late-breaker oral presentation on Saturday, Oct. 10, will report results on the investigational medicine's efficacy, safety and patient-reported outcomes.
Lilly to Showcase Data for Investigational Psoriasis Treatment at 24th European Academy of Dermatology and Venereology Congress (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.